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The Swedish Family-Cancer Database was used to quantify the incidence of second tumours in melanoma patients with a parental
history of cancer. Patients with parents affected by melanoma showed a 32.3-fold risk of second primary melanomas, which was
greater than a multiplicative interaction.
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Compared with other skin cancers, cutaneous melanoma (CM) is a
rare disease, with an incidence rate of 14 cases per 100000 in
Sweden, one of the highest rates in Europe (de Vries and Coebergh,
2004). In contrast, CM is responsible for 80% of all skin cancer-
related deaths (Miller and Mihm, 2006). The improvements in
survival after melanoma have resulted in an increased incidence of
subsequent primary tumour survival (Bhatia et al, 1999).
Melanoma patients are prone to develop second tumours in the
breast, prostate, kidney and skin, and particularly, second primary
melanomas (Schmid-Wendtner et al, 2001; Goggins and Tsao,
2003), but those with a parental history of cancer have not been
ascertained separately. The present population-based study
investigates the risk of type-specific second tumours after
diagnosis of melanoma and expands on the familial risk of
subsequent cancers. Apart from its importance for clinical
counselling and prevention, an understanding of the role of
parental history in multiple cancers may help to understand cancer
aetiology.
MATERIALS AND METHODS
The Swedish Family-Cancer Database, which was created in 1995
and last updated in 2006, includes a total of 11. 5 million
individuals. The Database covers offspring born or immigrated
after 1931 with information on biological parents (Hemminki et al,
2006). In this study, cancers were classified according to the 4-digit
diagnostic code from the seventh version of the International
Classification of Disease (ICD-7). Tumours are compulsorily
reported in Sweden and the agreement between clinical and
cytological or histological diagnoses is close to 100%.
In the present retrospective cohort study, follow-up started at
diagnosis of melanoma in a member of the offspring generation
and it ended at occurrence of death, emigration, the diagnosis of
any subsequent malignancy or 31 December 2004 (close date of the
study). Two types of parental history were investigated: a parental
history of melanoma (one of the two parents of the individual
diagnosed with malignant melanoma) and a concordant parental
history (one of the parents affected by the same type of cancer as
the second primary cancer in the offspring). Standardized
incidence ratios (SIR) were used to measure the relative risk of
second cancers and they were calculated as the ratio of observed
(O) to expected (E) number of cases. The expected numbers were
computed from the first primary cancer incidence rates taking into
account age (5-year intervals), region (four regions), calendar
period (1960–1964, 1965–1969,y, 2000–2004) and socio-eco-
nomic status (six groups). A Poisson distribution of the number of
cases was assumed. Multiplicative interaction indexes (MIIs) and
interaction contrast ratios (ICRs) were used to investigate the
possible interaction between ‘individual history of melanoma’ and
‘parental history of cancer’. If SIRmelanoma represents the relative
risk of cancer after melanoma, SIRph the relative risk in individuals
with a parental history of cancer and SIRmelanomaxph the relative
risk in melanoma patients with a parental history, MII¼
SIRmelanomaxph/(SIRmelanomaxSIRph) and ICR¼SIRmelanomaxfh-
SIRmelanoma-SIRphþ1. MII1 suggests departure from multiplica-
tivity and ICR0 indicates departure from additivity. Confidence
intervals and P-values for MII and ICR were calculated by
bootstrapping using 10000 replications. All statistical analyses
were carried out in SAS 9.1.
RESULTS
We identified 15581 individuals in the offspring generation
diagnosed with malignant melanoma before the age of 73 years
(registration of individuals started in 1931 and the last update of
the Database includes cancers diagnosed before year 2004). Among
the patients, 1156 developed a subsequent cancer. Table 1 shows
the SIRs for sites where at least 10 cases were observed. Compared
with the general Swedish population, an increased risk of second
cancer was observed for the breast (1.35), prostate (1.22), skin
(melanoma 9.03 and squamous cell 3.48) and nervous system
(1.66). Lymphohematopoietic neoplasms were also in excess,
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ymostly because of an increased risk of non-Hodgkin’s lymphoma
with an SIR of 1.60. A parental history of melanoma increased the
risk of second melanoma to an SIR of 32.3. The analysis of the
interaction between individual and parental history of melanoma
resulted in MII¼1.46 (95% CI 1.06 to 2.03, P¼0.03) and
ICR¼21.7 (95% CI 13.3–33.3, Po0.01), thus suggesting greater
than multiplicative and greater than additive interaction effects.
Table 2 shows the relative risks of site-specific cancers for
individuals with a parental family history of the particular cancer
(first column) and the parental risks of the same (concordant)
cancer after melanoma. For example, the relative risk of liver
cancer was 1.3 for the offspring of liver cancer patients, but the SIR
increased to 13.5 (two cases) when the offspring were melanoma
patients. The relative risk of breast cancer in women with affected
mothers was 1.64, and it increased to 2.51 among melanoma
patients with a maternal history of breast cancer. The interaction
between ‘individual history of melanoma’ and ‘maternal history of
breast cancer’ did not significantly depart from multiplicativity or
additivity (MII¼1.13 (95% CI 0.79–1.64, P¼0.29) and ICR¼0.52
(95% CI  0.24–1.59, P¼1.14)). Melanoma patients with a
Table 1 Relative risks of second neoplasms after melanoma in the general population and in patients with a parental history of melanoma
All offspring Offspring of melanoma patients
Type of second cancer N
a SIR
b (95% CI
c) N SIR (95% CI)
Any type 1156 1.74 1.64 1.85 53 3.59 2.69 4.69
Solid cancers 1089 1.76 1.66 1.87 51 3.71 2.76 4.88
Upper aerodigestive tract 16 1.50 0.86 2.45 1 4.12 0.00 23.6
Colorectum 54 0.99 0.74 1.29 1 0.88 0.00 5.06
Liver 11 1.19 0.59 2.14 0
Pancreas 13 1.17 0.62 2.07 1 4.46 0.00 25.6
Lung 34 0.82 0.57 1.15 2 2.33 0.22 8.59
Breast 206 1.35 1.17 1.55 5 1.46 0.46 3.44
Endometrium 17 0.73 0.42 1.17 1 2.30 0.00 13.2
Ovary 16 0.83 0.47 1.34 0
Prostate 111 1.22 1.01 1.47 3 1.51 0.29 4.48
Kidney 22 1.54 0.96 2.34 1 3.27 0.00 18.7
Urinary bladder 30 1.32 0.89 1.89 0
Melanoma 343 9.03 8.10 10.0 32 32.3 22.1 45.6
Skin, squamous cell 53 3.48 2.61 4.56 1 2.99 0.00 17.1
Nervous system 43 1.66 1.20 2.24 2 3.14 0.30 11.6
Lymphohaematopoietic neoplasms 67 1.50 1.16 1.90 2 1.92 0.18 7.07
Non-Hodgkin’s lymphoma 33 1.60 1.10 2.26 0
Myeloma 11 1.66 0.83 2.98 0
Leukaemia 16 1.06 0.60 1.72 1 2.85 0.00 16.3
aNumber of melanoma patients with second neoplasms.
bStandardised Incidence Ratio.
cConfidence interval. Bold type represents statistical significance at the 0.05 confidence level.
Table 2 Parental relative risks of cancer and relative risks of second neoplasms in melanoma patients with a parental history of concordant (same site)
cancer
Individuals with parents affected
by concordant cancer
Melanoma patients with parents affected
by concordant cancer
Type of second cancer N
a SIR
b (95% CI
c) N SIR (95% CI)
Any type 81548 1.05 1.05 1.06 629 1.93 1.78 2.09
Solid cancers 71104 1.06 1.05 1.07 557 1.95 1.79 2.12
Upper aerodigestive tract 49 1.67 1.26 2.22 0
Colorectum 1573 1.69 1.61 1.78 3 0.76 0.14 2.25
Liver 60 1.30 1.01 1.69 2 13.5 1.28 49.8
Pancreas 85 2.01 1.62 2.50 1 4.82 0.00 27.7
Lung 647 1.72 1.58 1.86 1 0.56 0.00 3.20
Breast 3656 1.64 1.59 1.70 25 2.51 1.62 3.71
Endometrium 163 2.16 1.85 2.52 1 3.07 0.00 17.6
Ovary 176 2.48 2.13 2.88 0
Prostate 2472 1.88 1.80 1.96 11 1.57 0.78 2.82
Kidney 119 2.19 1.82 2.62 3 13.1 2.47 38.7
Urinary bladder 279 1.79 1.58 2.01 2 3.25 0.31 12.0
Melanoma 438 2.44 2.22 2.68 32 32.3 22.1 45.6
Skin, squamous cell 172 2.03 1.74 2.36 2 4.04 0.38 14.8
Nervous system 257 1.69 1.50 1.92 1 2.23 0.00 12.8
Lymphohaematopoietic neoplasms 879 1.38 1.29 5 2.83 0.89 6.65
Non-Hodgkin’s lymphoma 167 1.86 1.60 2.17 2 6.33 0.60 23.3
Myeloma 35 2.43 1.74 3.40 0
Leukaemia 150 1.87 1.58 2.19 1 4.47 0.00 25.7
aNumber of cases with a parental history.
bStandardised Incidence Ratio.
cConfidence interval. Bold type represents statistical significance at the 0.05 confidence level.
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yparental history of kidney cancer were at very high risk of
developing second kidney cancers (SIR 13.1, three cases).
DISCUSSION
The present study, based on the nation-wide Swedish Family-
Cancer Database, focuses on the risk of subsequent cancer after
malignant melanoma in individuals with a parental history of
cancer. In agreement with previous studies, melanoma patients
were at an increased risk of second tumours, including melanomas
and lymphomas. The reasons for these increases are probably
manifold. Immune suppression induced by therapy, exposure to
ultraviolet radiation and the primary disease could explain some
cases, particularly for non-Hodgkin’s lymphoma (Ebbesen, 1981;
Romedahl et al, 1988; Hemminki et al, 2003). A novel result of this
study was the increased risk observed for squamous cell
carcinoma. This association has been previously observed in a
reversed sequence: increased risk of melanoma after squamous cell
carcinoma (Hemminki and Dong, 2000). In addition to treatment-
related factors, unidentified susceptibility genes could explain
these results to some extent. Inactivation of CDKN2A by genetic
and epigenetic changes has been described in melanoma,
squamous cell carcinoma, breast cancer and Hodgkin disease
(Soufir et al, 1999; Brown et al, 2004; Debniak et al, 2007; Sinha
et al, 2008). However, the association between germline mutations
in CDKN2A and malignancies other than melanoma are still
unclear. Mutations in MC1R, a low-penetrance melanoma-predis-
posing gene, could also be involved in squamous cell skin cancers
and in Hodgkin’s disease (Palmer et al, 2000; Box et al, 2001; Figl
et al, 2007). The novel data from the present study refer to the risk
of second concordant tumours in melanoma patients with a
parental history of cancer. The risks were increased for second
liver and kidney cancers after melanoma when the parents were
diagnosed with liver or kidney cancer, respectively; however, the
number of cases was small. More convincingly, a greater than
additive and greater than multiplicative interaction was observed
between parental and individual history of melanoma, with an
expected SIR of 2.44 8.41¼20.5 and an observed SIR of 32.3 (the
SIR of second melanoma for individuals without a parental history
was 8.41, 311 cases, 95% confidence interval: 7.50–9.40, data not
shown). A study based on a previous version of the Database
showed that, when mothers had breast cancer and fathers
melanoma, the offspring was at a high risk of both breast cancer
and melanoma (Hemminki and Vaittinen, 1997). The present data
could mirror the effects of gene-environment interactions – for
example, between CDKN2A mutations and UV-exposure – or the
combinations among yet unidentified susceptibility genes.
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